Gentisic acid ethanolamine | 7491-35-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Gentisic acid ethanolamine
• 英文别名: 2-aminoethanol;2,5-dihydroxybenzoic acid
• CAS: 7491-35-2
• 化学式: C9H13NO5
• 分子量: 215.2
• InChiKey: AKTFIQYVASYRMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.27
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  124
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• PHARMACEUTICAL COMPOSITION OF PEMETREXED
  申请人：Fresenius Kabi Oncology Ltd

  公开号：EP3210629A1

  公开（公告）日：2017-08-30

  A pharmaceutical composition of Pemetrexed represented by formula (I), which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more pharmaceutically acceptable excipients. Also provided are processes for preparation of the ready to use solution formulation or lyophilized pharmaceutical composition of the present invention.

  一种由式(I)代表的培美曲塞药物组合物，它是一种液体即用型溶液制剂或用于肠外给药的冻干药物组合物，其中包含一种药学上可接受的有机胺、一种惰性气体，并可选择地包含至少一种或多种药学上可接受的赋形剂。此外，还提供了制备本发明的即用溶液制剂或冻干药物组合物的工艺。
• Daptomycin formulations and uses thereof
  申请人：HOSPIRA AUSTRALIA PTY LTD

  公开号：US10357535B2

  公开（公告）日：2019-07-23

  Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations.

  冻干达托霉素制剂具有更好的复溶时间。冻干达托霉素制剂包括一种添加剂，可以是药学上可接受的抗氧化剂、药学上可接受的有机酸或其药学上可接受的盐、药学上可接受的葡萄糖衍生物或其药学上可接受的盐，或它们的组合。还提供了制备冻干达托霉素制剂的方法，以及使用冻干达托霉素制剂治疗细菌感染和治疗或预防生物膜的方法。
• Quinolone analogs and their salts, compositions, and method for their use
  申请人：Senhwa Biosciences, Inc.

  公开号：US11524012B1

  公开（公告）日：2022-12-13

  The present invention includes a solid lyophilized form of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) and the process of producing the solid lyophilized form. Furthermore, the present invention provides compositions comprising Compound I, or a pharmaceutically acceptable salt and/or solvate thereof and therapeutic use of the composition.

  本发明包括 2-(4-甲基-[1,4]二氮杂环庚烷-1-基)-5-氧代-5H-7-硫杂-1,11b-二氮杂-苯并[c]芴-6-羧酸(5-甲基吡嗪-2-基甲基)-酰胺(化合物 I)的固体冻干形式以及该固体冻干形式的生产工艺。此外，本发明还提供了包含化合物I或其药学上可接受的盐和/或溶液的组合物以及该组合物的治疗用途。
• [EN] QUINOLONE ANALOGS AND THEIR SALTS, COMPOSITIONS, AND METHOD FOR THEIR USE<br/>[FR] ANALOGUES DE QUINOLONE, SELS CORRESPONDANTS, COMPOSITIONS ET PROCÉDÉ D'UTILISATION
  申请人：SENHWA BIOSCIENCES INC

  公开号：WO2019168688A9

  公开（公告）日：2019-11-14
• PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED TOGETHER WITH MONOTHIOGLYCEROL, L-CYSTEIN OR THIOGLYCOLIC ACID
  申请人：ELI LILLY AND COMPANY

  公开号：EP1265612A1

  公开（公告）日：2002-12-18